Melbourne, Australia
Melbourne, Australia

Time filter

Source Type

Patent
Hatchtech | Date: 2012-05-30

A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.


Patent
Hatchtech | Date: 2014-12-17

The disclosure provides a pediculicidal composition comprising a metal chelating agent; a carrier vehicle comprising water and an activating solvent system comprising an alcohol and a hydrocarbon. The carrier vehicle may be in the form of a solution, a cream, an ointment, a foam, a spray, an emulsion or a gel. The disclosure also provides method for use of a pediculicidal composition to treat human head lice and their eggs and methods for controlling head lice infestation.


Patent
Hatchtech | Date: 2016-06-03

A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the, compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.


Patent
Hatchtech | Date: 2010-10-12

A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.


A climate chamber for the treating of products with a conditioned gas stream includes a substantially closed compartment having two opposing lateral walls provided with one or more passages; a substantially closed channel which extends around the outside of the compartment and connects one of said lateral walls to the other of said lateral walls in order to form together with the compartment a substantially closed circuit; and a gas displacement device received in the substantially closed channel for circulating the conditioned gas stream through the circuit. The gas displacement device is provided with a reversing system configured for reversing repeatedly, in each case once a reversing time interval has elapsed, the direction in which the conditioned gas stream is circulated through the circuit. The gas stream passes through the compartment predominantly from one lateral wall to the other lateral wall.


The invention relates to the use of a cyclone separator for separating keratin particles originating from poultry out of a gas, in particular air. The separated particles comprise down particles. The invention furthermore relates to a climate chamber for hatching eggs and/or keeping poultry. Said climate chamber comprises a substantially closed compartment having two opposite side walls provided with one or more passages; as well as a substantially closed duct which extends outside the compartment and connects one of said side walls to the other of said side walls so as to form a substantially closed circuit together with the compartment. Said climate chamber furthermore comprises a cyclone separator, the inlet of which ends in the substantially closed duct and the outlet of which ends outside the closed duct for discharging into the environment.


Patent
Hatchtech | Date: 2014-02-13

The invention relates to a tray (1) for containing a number of eggs (2) in an incubation chamber, the tray comprising a number of egg accommodation spaces (3) in which space an egg is able to be hatched, and at least one passage (4) for a chicken through which passage a chicken hatched from said egg may pass through the tray and enter a chicken accommodation space located below the tray.


Patent
Hatchtech | Date: 2012-07-02

A method for inhibiting hatching of an ectoparasite egg, the method comprising exposing the ectoparasite egg to at least one metal chelating agent and/or metalloprotease inhibitor, wherein the metal chelating agent is a compound comprising at least two heteroatoms able to simultaneously coordinate with a metal ion, at least one of the two heteroatoms being selected from nitrogen, sulfur, oxygen and phosphorus, wherein the compound comprises at least one carbocyclic ring substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom, or the compound comprises at least one heterocyclic ring containing at least one heteroatom, wherein said heterocyclic ring is optionally substituted with at least one heteroatom and/or with a substituent containing at least one heteroatom is provided. Methods of treating ectoparasite infestations and compositions for use in such methods are also provided.


News Article | September 13, 2015
Site: www.smh.com.au

Australian pharmaceutical company Hatchtech has inked a deal worth up to $279 million with Indian giant Dr. Reddy's for the commercialisation of its innovative head lice treatment. Dr Reddy's Laboratories, a $US10.3 billion ($14.5 billion) integrated pharmaceutical group listed in New York, will pay Hatchtech an undisclosed upfront fee, up to $85 million in pre-commercialisation milestone payments, and the remainder of the $279 million subject to sales-based milestones. Hatchtech chief executive Hugh Alsop told Fairfax Media that the deal, which follows two other recent deals by venture capital backed firms, is further proof that Australian research can get from the university lab to market. "This success is another good success for the VC [venture capital] market. We'd like to think we are the third successful VC exit in 12 months," he said. In June, Swiss pharmaceutical giant Novartis pounced on Australian biotech Spinifex Pharma, which was founded on research done in the University of Queensland, in a deal worth up to $US700 million. Last year,Melbourne drug developer Fibrotech was snapped up by pharmaceutical group Shire in a deal worth up to $500 million. "For those people out there who doubt that VC land can commercialise technology, these examples show that the VC sector can work," Mr Alsop said. Hatchtech was founded in 2001 by Dr Vern Bowles, who is the company's chief science officer and deputy director of the centre for animal biotechnology at the University of Melbourne. The company was seed funded by Uniseed, the venture capital arm of the Universities of Melbourne, Queensland and NSW. Other investors in Hatchtech include QIC and venture capital firms OneVentures, GBS Ventures, and Blue Sky. OneVentures owns 37 per cent of the company. Aside from its investment via Uniseed, Melbourne University's endowment fund also owns a separate 14 per cent stake. OneVentures led each funding round for Hatchtech and will return up to $100 million to investors following the deal. OneVentures managing director Dr Paul Kelly said the deal has secured a commercialisation path for Xeglyze. "The OneVentures approach has not only maximised the value for shareholders, it has enhanced the experience in later-stage drug development of the researchers and the executive team involved, who will continue to reinvest their rich skills to advance other novel therapies," Dr Kelly said. On Monday Hatchtech will file its new drug application with the US Food & Drug Administration for its Xeglyze Lotion, the head lice treatment developed by Dr Bowles and Hatchtech. This crucial step follows 11 human clinical trials and a series of animal studies. Mr Alsop, who took on the CEO job in 2013, said that getting to this stage in the FDA process itself is an achievement. "There are only about 10 Aussie companies that have got their product through to be submitted to the drug admission entity of the FDA," he said. "Last year the FDA only approved 41 new drugs and the average over the last 10 years has been about 25 [new drugs a year]." Mr Alsop, who worked at Acrux in 2010 when it signed a $US335 million commercialisation deal with Eli Lilley, was brought on board to help negotiate Xeglyze's path to market. Including over-the-counter products, prescription treatments, and home remedies, there are about 7 million head lice treatments in the United States every year. Hatchtech's Xeglyze Lotion is a prescription treatment, and the annual gross sales in this part of the US market are approximately $US100 million a year. Mr Alsop said he is confident Xeglyze will become the clear market leader. "Our product kills the eggs as well as killing the lice and no competing product has that attribute," he said. In addition to its VC backers, Hatchtech also received funding via the now defunct federal government Innovation Investment Fund (IIF) program and from the R&D tax credit scheme. There have been increasingly vocal calls from both researchers and the handful of venture capital investors for the Abbott government to reverse its cuts and start funding commercialisation programs again. Mr Alsop said the IIF program should "absolutely" be reinstated and good policies like the R&D tax credit should be protected. "I like to think Hatchtech is an example of how we can capitalise if the policy settings are right," he said. Hatchtech will retain global rights for non-human applications of Xeglyze and the rights for human treatment outside the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela. Developing uses for the treatment of animals, such as in treating fleas, ticks, and lice, will be a key focus for Hatchtech going forward.

Loading Hatchtech collaborators
Loading Hatchtech collaborators